XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
CONDENSED COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (46,934) $ (22,374)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 516 218
Stock-based compensation expense 11,213 1,756
Write-down of inventory 0 33
Payments received on net investment in lease 4 5
Changes in assets and liabilities:    
Accounts receivable (1,434) (263)
Unbilled receivables (1,027) (39)
Inventory (336) (449)
Prepaid expenses and other current assets (1,213) (357)
Due from related parties 12 1,279
Other assets - related party   193
Other long term assets 52 (20)
Accounts payable (551) 196
Deferred grant funding (1,058) (322)
Deferred revenue 469 554
Due to related parties (1,900) (50)
Accrued expenses and other current liabilities (2,013) 536
Net cash used in operating activities (44,200) (19,104)
Cash flows from investing activities:    
Purchases of fixed assets (254) (675)
Net cash used in investing activities (254) (675)
Cash flows from financing activities:    
Proceeds from exercise of stock options 2 198
Proceeds from issuance of Series D convertible preferred stock   30,468
Stock issuance costs related to Series D convertible preferred stock   (7)
Investment from 4Bionics, LLC   3,516
Net cash provided by financing activities 2 34,175
Net (decrease) increase in cash and cash equivalents and restricted cash (44,452) 14,396
Cash, cash equivalents and restricted cash, beginning of period 191,160 64,286
Cash, cash equivalents and restricted cash, end of period 146,708 78,682
Reconciliation of cash, cash equivalents, and restricted cash reported in the statement of financial position    
Cash and cash equivalents 145,104 77,394
Restricted cash 1,604 1,288
Total cash, cash equivalents and restricted cash 146,708 78,682
Supplemental disclosure of cash flow information:    
Cash received from exchange of research and development tax credits   $ 324
Supplemental disclosure of noncash information:    
Write-off of notes receivable $ 90